Edition:
United Kingdom

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

14.80USD
13 Dec 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$14.80
Open
$15.19
Day's High
$15.45
Day's Low
$14.36
Volume
673,835
Avg. Vol
657,002
52-wk High
$22.38
52-wk Low
$3.01

Latest Key Developments (Source: Significant Developments)

Arrowhead Pharmaceuticals Inc Quarterly Loss Per Share $0.12
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.12.ARROWHEAD PHARMACEUTICALS INC QUARTERLY REVENUES $11.26 MILLION VERSUS $8.7 MILLION.  Full Article

Arrowhead Pharmaceuticals Inc Files For Offering Of Up To 3.3 Mln Shares Of Common Stock
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 3.3 MILLION SHARES OF COMMON STOCK - SEC FILING.  Full Article

Arrowhead Pharmaceuticals Quarterly Net Loss Per Share $0.18
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 THIRD QUARTER RESULTS.ARROWHEAD PHARMACEUTICALS INC QUARTERLY NET LOSS PER SHARE $0.18.ARROWHEAD PHARMACEUTICALS INC QUARTERLY REVENUE $727,375 VERSUS $9.34 MILLION.  Full Article

Arrowhead Pharmaceuticals Earns $10 Mln Milestone Payment From Amgen
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS SAYS EARNED $10 MILLION MILESTONE PAYMENT FROM AMGEN FOLLOWING ADMINISTRATION OF FIRST DOSE OF AMG 890.  Full Article

Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline
Friday, 11 May 2018 

May 11 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON EXPANDING CARDIOMETABOLIC PIPELINE.ARROWHEAD PHARMACEUTICALS - INTENDS TO FILE CLINICAL TRIAL APPLICATIONS FOR ARO-ANG3 & ARO-APOC3 BEFORE END OF 2018.  Full Article

Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.18
Tuesday, 8 May 2018 

May 8 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 SECOND QUARTER RESULTS.QTRLY LOSS PER SHARE $0.18.Q2 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.  Full Article

Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 10.0 MILLION COMMON SHARES PRICED AT $5.25PER SHARE.  Full Article

Arrowhead Pharma Announces Proposed Underwritten Offering Of Common Stock
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN OFFERING OF COMMON STOCK.  Full Article

Silence Therapeutics ‍Sells Further Stake In Arrowhead Pharmaceuticals ​
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Silence Therapeutics Plc ::‍SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.​.DEAL ‍FOR A TOTAL CONSIDERATION OF $11.3 MILLION​.  Full Article

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT.ARROWHEAD PHARMACEUTICALS INC - APPLICATION FOR APPROVAL OF CLINICAL TRIAL WAS SUBMITTED TO NEW ZEALAND MEDICINES AND MEDICAL DEVICES SAFETY AUTHORITY.  Full Article

Photo

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion (2.8 billion pounds), sending its shares surging 20 percent.